![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CELLULAR AND MOLECULAR
Departments of Vascular Biology (E.H., Z.C., J.K., M.J.), Genetic Technologies (E.D., R.K., G.-F.Z., K.J.), Oncology (C.-M.S., J.W.), Medicinal Chemistry (R.L., A.L.), and Screening Sciences (G.H., R.M., M.D.L.F., P.P.), GlaxoSmithKline Pharmaceuticals, King of Prussia, Pennsylvania
Histone deacetylases (HDACs) represent an expanding family of protein modifying-enzymes that play important roles in cell proliferation, chromosome remodeling, and gene transcription. We have previously shown that recombinant human HDAC8 can be expressed in bacteria and retain its catalytic activity. To further explore the catalytic activity of HDACs, we expressed two additional human class I HDACs, HDAC1 and HDAC3, in baculovirus. Recombinant HDAC1 and HDAC3 fusion proteins remained soluble and catalytically active and were purified to near homogeneity. Interestingly, trichostatin (TSA) was found to be a potent inhibitor for all three HDACs (IC50 value of 
0.1-0.3 µM), whereas another HDAC inhibitor MS-27-275 (N-(2-aminophenyl)-4-[N-(pyridin-3-methyloxycarbonyl)-aminomethyl]benzamide) preferentially inhibited HDAC1 (IC50 value of 0.3 µM) versus HDAC3 (IC50 value of 8 µM) and had no inhibitory activity toward HDAC8 (IC50 value >100 µM). MS-27-275 as well as TSA increased histone H4 acetylation, induced apoptosis in the human colon cancer cell line SW620, and activated the simian virus 40 early promoter. HDAC1 protein was more abundantly expressed in SW620 cells compared with that of HDAC3 and HDAC8. Using purified recombinant HDAC proteins, we identified several novel HDAC inhibitors that preferentially inhibit HDAC1 or HDAC8. These inhibitors displayed distinct properties in inducing histone acetylation and reporter gene expression. These results suggest selective HDAC inhibitors could be identified using recombinantly expressed HDACs and that HDAC1 may be a promising therapeutic target for designing HDAC inhibitors for proliferative diseases such as cancer.
Address correspondence to: Dr. Erding Hu, Rm. 25-1084, Department of Vascular Biology, GlaxoSmithKline, 709 Swedeland Rd., King of Prussia, PA 19406. E-mail: erding_hu-1{at}gsk.com
This article has been cited by other articles:
|
|
 |
|
  C. J. Chou, D. Herman, and J. M. Gottesfeld Pimelic Diphenylamide 106 Is a Slow, Tight-binding Inhibitor of Class I Histone Deacetylases J. Biol. Chem., December 19, 2008; 283(51): 35402 - 35409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Haumaitre, O. Lenoir, and R. Scharfmann Histone Deacetylase Inhibitors Modify Pancreatic Cell Fate Determination and Amplify Endocrine Progenitors Mol. Cell. Biol., October 15, 2008; 28(20): 6373 - 6383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Su, L. Altucci, and Q. You Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schuetz, J. Min, A. Allali-Hassani, M. Schapira, M. Shuen, P. Loppnau, R. Mazitschek, N. P. Kwiatkowski, T. A. Lewis, R. L. Maglathin, et al. Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity J. Biol. Chem., April 25, 2008; 283(17): 11355 - 11363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. T. Andrews, T. N. Tran, A. J. Lucke, P. Kahnberg, G. T. Le, G. M. Boyle, D. L. Gardiner, T. S. Skinner-Adams, and D. P. Fairlie Potent Antimalarial Activity of Histone Deacetylase Inhibitor Analogues Antimicrob. Agents Chemother., April 1, 2008; 52(4): 1454 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fournel, C. Bonfils, Y. Hou, P. T. Yan, M.-C. Trachy-Bourget, A. Kalita, J. Liu, A.-H. Lu, N. Z. Zhou, M.-F. Robert, et al. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther., April 1, 2008; 7(4): 759 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zimmermann, F. Kiefer, M. Prudenziati, C. Spiller, J. Hansen, T. Floss, W. Wurst, S. Minucci, and M. Gottlicher Reduced Body Size and Decreased Intestinal Tumor Rates in HDAC2-Mutant Mice Cancer Res., October 1, 2007; 67(19): 9047 - 9054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Dompierre, J. D. Godin, B. C. Charrin, F. P. Cordelieres, S. J. King, S. Humbert, and F. Saudou Histone Deacetylase 6 Inhibition Compensates for the Transport Deficit in Huntington's Disease by Increasing Tubulin Acetylation J. Neurosci., March 28, 2007; 27(13): 3571 - 3583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Vlasakova, Z. Novakova, L. Rossmeislova, M. Kahle, P. Hozak, and Z. Hodny Histone deacetylase inhibitors suppress IFN{alpha}-induced up-regulation of promyelocytic leukemia protein Blood, February 15, 2007; 109(4): 1373 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Inoue, A. Mai, M. J.S. Dyer, and G. M. Cohen Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis. Cancer Res., July 1, 2006; 66(13): 6785 - 6792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. A. Cao, K. E. Bass, S. Balasubramanian, L. Liu, B. Schultz, E. Verner, Y. Dai, R. A. Molina, J. R. Davis, S. Misialek, et al. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo. Mol. Cancer Ther., July 1, 2006; 5(7): 1693 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. V. Simonini, L. M. Camargo, E. Dong, E. Maloku, M. Veldic, E. Costa, and A. Guidotti From The Cover: The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases PNAS, January 31, 2006; 103(5): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Qiu, R. P. Ritchie, Z. Fu, D. Cao, J. Cumming, J. M. Miano, D.-Z. Wang, H. J. Li, and L. Li Myocardin Enhances Smad3-Mediated Transforming Growth Factor-{beta}1 Signaling in a CArG Box-Independent Manner: Smad-Binding Element Is an Important cis Element for SM22{alpha} Transcription In Vivo Circ. Res., November 11, 2005; 97(10): 983 - 991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Acharya, A. Sparreboom, J. Venitz, and W. D. Figg Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review Mol. Pharmacol., October 1, 2005; 68(4): 917 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wang, H. M. Curry, B. S. Zwilling, and W. P. Lafuse Mycobacteria Inhibition of IFN-{gamma} Induced HLA-DR Gene Expression by Up-Regulating Histone Deacetylation at the Promoter Region in Human THP-1 Monocytic Cells J. Immunol., May 1, 2005; 174(9): 5687 - 5694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Lagace and M. W. Nachtigal Inhibition of Histone Deacetylase Activity by Valproic Acid Blocks Adipogenesis J. Biol. Chem., April 30, 2004; 279(18): 18851 - 18860. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
